Login to Your Account



It's Phase III that Counts

Despite Concerns Threshold Moves Cancer Drug Along

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, October 8, 2012

Threshold Pharmaceuticals Inc.'s data for TH-302 in pancreatic cancer isn't perfect, but the biotech and its partner Merck KGaA think the Phase IIb results are good enough to justify pushing the drug into a Phase III trial for the indication.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription